Edwards LifesciencesEW +3.12%97 Net Margin % is 23.09% as of Mar. 2026, which is 6% above its 10-year median of 21.74. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.14 (Fairly Valued). The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Edwards Lifesciences ranks better than 86.54% on this metric.
The historical rank and industry rank for Edwards Lifesciences's Net Margin % or its related term are showing as below:
EW'
s Net Margin % Range Over the Past 10 Years
Min: 16.99 Med: 21.74 Max: 76.75
Current: 17.34
EW's Net Margin % is ranked better than 86.54% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs EW: 17.34
Edwards Lifesciences (NYSE:EW) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Edwards Lifesciences Net Margin % Related Terms
Edwards Lifesciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Edwards Lifesciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (EW) has a Net Margin % of 23.09% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Edwards Lifesciences and its competitors. This is near median its historical median of 21.74. Over the past decade, Edwards Lifesciences' Net Margin % has ranged from 16.99 to 76.75. According to the industry distribution chart, Edwards Lifesciences ranks #110 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 13.5%.
Is Edwards Lifesciences' Net Margin % too high?
Edwards Lifesciences' current Net Margin % of 23.09% is near median its 10-year median of 21.74. Over the past 10 years, this metric has ranged from a low of 16.99 to a high of 76.75. The Medical Devices & Instruments industry median Net Margin % is 2.07. Edwards Lifesciences' value of 23.09% is 1015.5% above this industry median. Based on the distribution chart, Edwards Lifesciences ranks #110 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Net Margin % compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #110 out of 817 companies for Net Margin %. This places Edwards Lifesciences in the top 14% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.07. Edwards Lifesciences' value of 23.09% is 1015.5% above this benchmark. Historically, Edwards Lifesciences' own Net Margin % has ranged from 16.99 to 76.75 over the past decade. While the company's 10-year median is 21.74 vs. the industry median of 2.07, Edwards Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current Net Margin % of 23.09% is 1015.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Net Margin % is 23.09%, which is near median its own 10-year median of 21.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $93.14, compared to a current price of $89.66 — trading 3.7% below its estimated fair value. The current Net Margin % is 23.09%, which is near median its 10-year median of 21.74 and 1015.5% above the Medical Devices & Instruments industry median of 2.07. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current Net Margin % is 23.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of $89.66 is trading 3.7% below its estimated GF Value™ of $93.14.
GuruFocus considers Edwards Lifesciences to be Fairly Valued.
Key valuation signals for EW:
Net Margin %: 23.09% (near median its 10-year median of 21.74)
GF Value™: $93.14 vs. price of $89.66 (3.7% below fair value)
Industry Position: 1015.5% above the Medical Devices & Instruments median (#110 of 817)
No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for EW
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EW has been successfully added to your 
